Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Assets (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Non-Current Assets for 8 consecutive years, with $40.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $40.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $40.5 million, a N/A change, with the full-year FY2023 number at $12.4 million, up 131.25% from a year prior.
  • Other Non-Current Assets was $40.5 million for Q3 2025 at Akebia Therapeutics, up from $12.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $69.6 million in Q3 2021 to a low of $3.3 million in Q2 2023.
  • A 4-year average of $30.6 million and a median of $35.0 million in 2022 define the central range for Other Non-Current Assets.
  • Biggest YoY gain for Other Non-Current Assets was 131.25% in 2023; the steepest drop was 90.42% in 2023.
  • Akebia Therapeutics' Other Non-Current Assets stood at $50.4 million in 2021, then crashed by 89.35% to $5.4 million in 2022, then soared by 131.25% to $12.4 million in 2023, then skyrocketed by 225.7% to $40.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Non-Current Assets are $40.5 million (Q3 2025), $12.4 million (Q4 2023), and $3.9 million (Q3 2023).